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Background: Ulcerative colitis (UC) is a systemic disease of unknown etiology with extra-intes-
tinal manifestation. Induced sputum (IS) non-invasively assesses extrapulmonary involvement
in Crohn’s disease. We sought to determine whether there is a cellular marker of lung injury in
UC patients detectable by IS.
Methods: Nineteen UC patients (mean age 46.4 11.3 years, disease duration 8.6 7.5 years
[range 1e25 years] 68.4% males) were studied, 6 with active disease and 13 in remission.
Eleven received 5-ASA, 5 received steroids and/or azathioprine and 3 patients were untreated.
UC patients were compared with 27 healthy non-smoker controls. IS was recovered after
20 min inhalation of 3% saline with an ultrasonic nebulizer by the selecting plugs method,
and 300 cells were differentially cell counted in cytospin Giemsa-stained slides. CD4/CD8
subsets were identified by FACS. Pulmonary function tests were performed by the Jaeger Mas-
terlab spirometer.
Results: UC patients’ IS contained higher %eosinophils than controls (pZ 0.05) and lower
FEV1/FVC ratios (pZ 0.001). Steroid- and/or azathioprine-treated patients had significantly
lower FEV1/FVC ratios than only 5-ASA-treated patients (pZ 0.019). Eosinophil infiltration in
airways was high in 5-ASA-treated patients compared to those receiving steroids and/or azathi-
oprine (pZ 0.046) and those with less extensive disease (pZ 0.05). Using a cutoff of 3% eosin-
ophils, IS had a sensitivity of 67% and specificity of 73% to differentiate patients with a cutoff
of 70 eosinophils/mm2 in biopsy.3988; fax: þ972 3 4601.
alth.gov.il (E. Fireman).
9 Elsevier Ltd. All rights reserved.
1026 E. Fireman et al.Conclusions: The percentage of sputum eosinophils is significantly different between UC
patients with proctitis and pancolitis. These immune abnormalities may be a common pattern
that is present throughout the mucosae.
ª 2009 Elsevier Ltd. All rights reserved.Table 1 Clinical characteristics of the 19 ulcerative colitis
(UC) study patients.
Age (years) 46.4 11.3
Sex (M/F) 13/6
Smoking 6Introduction
Ulcerative colitis (UC) is a chronic inflammatory disorder of
the gastrointestinal (GI) tract that involves the large bowel.
The etiology of UC is presently unknown. Patients with UC
commonly present with a wide range of systemic and extra-
intestinal manifestations, most commonly involving the
skin, eyes, mouth, joints, and liver1 and less commonly
having clinically relevant bronchopulmonary manifesta-
tions.2 Several studies suggested that patients with
inflammatory bowel diseases (IBDs) have altered pulmonary
function tests (PFTs).3,4 It was recently shown that patients
with UC have decreased functional parameters, especially
the ones with active disease.5
Inflammatory changes were shown in the bron-
choalveolar lavage (BAL) fluid of IBD patients: alveolar
lymphocytosis was evident in fluid from Crohn’s disease
(CD) patients without respiratory symptoms,6 and mixed
inflammatory cells were revealed in the BAL fluid of UC
patients.7 BAL is an important tool for evaluating lung
disease8 but, being an invasive technique, it is unsuitable
for screening asymptomatic patients. The only noninvasive
method to directly study inflammatory processes in the lung
is the examination of sputum.9
We had previously shown that induced sputum (IS) was
useful for identifying a high (65%) incidence of CD4T
lymphocyte infiltration in the airways of CD patients who
had no respiratory symptoms.10 The IS technique has also
revealed the presence of bronchial eosinophilic infiltration
in CD patients.11
We hypothesized that UC is a T-helper lymphocyte 2 (Th2)
disease, while CD is mainly a T-helper lymphocyte 1 (Th1)
disease.12 We originally designed the current study to non-
invasively search for a cellular marker in the airways that can
best reflect the clinical condition in patients with UC.Documented lung diseases 3
UCDAI
Remissiona 9 patients (47.4%)
Active diseaseb 10 patients (52.6%)
Treatmentc
5-Aminosalicylic acid 11 patients
Prednisolone (oral) 4 patients
Betamethasone enema 4 patients
Azathioprine 1 patient
No treatment 3 patients
Extent of UC
Proctitis 7 patients
Extensive 9 patients
Pancolitis 3 patients
Duration of disease 8.6 7.5 years
UCDAI e Ulcerative Colitis Disease Activity Index (based on
criteria of Truelove and Witts14).
a UCDAI score 2.
b UCDAI score> 2.
c Some of the patients receive more than one medication.Methods
Selection of patients
There were 19 UC patients (male 68.4%), of whom 13 were
non-smokers and 6 were present or past smokers. Their
mean age was 46.4 11.3 years and the mean disease
duration was 8.6 7.5 years (range 1e25 years). Three had
asymptomatic bronchial asthma (not treated at the time of
recruitment), while none of the remaining 16 reported
respiratory symptoms. They were all diagnosed by clinical,
endoscopic and historical histological criteria.13 The
activity of the disease index we used ranged from 0 to 12,
with the higher total scores representing more severe
disease. The index was based on the Ulcerative Colitis
Disease Activity Index (UCDAI) of Truelove and Witts.14 In
general, a patient is considered to be in remission if the
UCDAI score is 2 and to have severe disease if the score is>10. Nine patients (47.4%) had UCDAI scores 2 (remission)
and the other 10 patients had active diseases (UCDAI> 2),
of whom 7 (36.8%) had proctitis. Twelve patients (63.2%)
had extensive UC (3 of them had pancolitis). Sixteen
patients were treated: 11 received 5-aminosalicylic acid (5-
ASA) 2e4 g/day, 4 received prednisolone (mean 20 mg/
day), 4 received betamethasone 5 mg/day by enema, 1 was
taking azathioprine 100 mg/day and 3 were not taking any
medications. Some of the patients were taking more than
one medication (Table 1).
The control group comprised 27 apparently healthy non-
smokers (mean age 35.4 9.7 years) without any known
respiratory disease, who were recruited from the hospital
staff. All participants signed informed consent forms and
the study was approved by the Institutional Review Board of
the Tel-Aviv Sourasky Medical Center and Hillel Yaffe
Medical Center.
Study design
Pulmonary function tests (PFTs; spirometry, lung volumes
and diffusion capacity) were performed by a Masterlab
(Masterlab E. Jaeger, Wurzburg, Germany). Measurement
was carried out using standard protocols according to the
American Thoracic Society guidelines.15
Sputum induction was carried out by an aerosol of
hypertonic saline generated by a DeVilbiss Aerosonic
Eosinophils in IS: an intestinal injury marker? 1027Ultrasonic Nebulizer 5000D/5000I (DeVilbiss-Health Care
Corporation Somerset, PA, USA) with an output of 0.5 ml/
min and a particle size of <5 mm aerodynamic mass median
diameter, using a slightly modified version of the method of
Pin et al.16 Briefly, subjects inhaled nebulized 3% saline for
up to 20 min delivered by an ultrasonic nebulizer through
a mouthpiece without a valve or noseclip. Ten minutes
after the start of nebulization and every 5 min thereafter,
the subjects were asked to rinse their nose and mouths with
water to minimize contamination of the nasal secretion
with saliva. They were encouraged to cough and expecto-
rate sputum into a sterile plastic container. The nebuliza-
tion was stopped after 20 min had elapsed or earlier if the
sputum sample was of sufficiently good quality. The sputum
was collected prior to any treatment.
The method of sputum examination described by Popov
et al.17 was used with some modifications. Sputum was
processed as soon as possible, always within 2 h. It was
poured onto a Petri dish and all portions with few or non-
squamous epithelial cells that were considered to originate
from the lower respiratory tract were selected under an
inverted microscope and placed in an Eppendorf tube,
whereupon the weight was recorded. Dithiothreitol (DTT;
Sputalysin, Calbiochem Corp., San Diego, CA, USA) was
freshly prepared in a dilution of 1:10 with distilled water
according to the manufacturer’s instructions. The volume
added was twice the recorded weight of the plugs, and it
was mixed mechanically with the sputum by aspiration in
and out of a pipette about 20 times to ensure an adequate
blend. The sample was then placed in a shaking water bath
at 37 C for 15 min to ensure complete homogenization. To
stop the effect of DTT, the suspension was further diluted
with phosphate-buffered solution (PBS) to a volume equal
to the sputum plus DTT. The cell suspension was filtered
through 52-mm nylon gauze (BNSH Thompson, Scarborough,
Ontario, Canada) to remove debris and mucus, and the
volume of the filtrate was recorded. The total cell count
was measured by a hemocytometer (Neubauer chamber).
The filtered cell suspension was centrifuged and the
supernatants were stored at 80 C until examination. The
pellet was diluted with RPMI supplemented with 10% fetal
calf serum (FCS, Biological Industries, Beit Haemek, Israel)
to achieve a concentration of 10/ml. One drop was placed in
each cytocentrifuge cup which is already in place in
a Shandon III cytocentrifuge (Shandon Southern Instru-
ments, Sewickley, PA, USA). Separate cytospin slides were
stained by Giemsa. The cell counts were performed by
scanning the cytospins, starting at the top left corner and
continuing in an undulating manner from top to bottom
while moving across the slide using high power (100)
magnification. Two-hundred nonsquamous cells were
counted, and the results were expressed as a percentage of
the total nonsquamous count.
For the evaluation of phenotype of sputum cells, flow
cytometric analysis was performed on a dual FACS 440
equipped with an Arþ and Kr laser (BectoneDickinson).
Data were collected and analyzed using the Consort VAX
and Disp4 and Disp2D programs (BectoneDickinson). The
information was collected on a logarithmic scale. The
selection of lymphocyte population was based on side
scatter, and expressions of CD45 lymphocytic subsets were
identified by monoclonal antibodies as follows: CD3Z totalT-cells, CD4Z T-helper cells, and CD8Z T suppressore
cytotoxic cells. Monoclonal antibodies were directly
conjugated to either phycoerythrin (RD1) or fluorescein
isothiocyanate (FITC). The cells were incubated for 10 min
with Epics Coulter Q-Prep and read either immediately or
24 h later.
For the evaluation of eosinophils in tissue biopsy, one
section was separately stained with Vital New Red (VNR)
according to the method of Li et al.18 Counts were carried
out from 5 selected areas, and the results were averaged
for each patient and converted to cells/mm2. The VRN stain
plus the counterstain allowed obtaining both the total
lamina propria cell density (103/mm2) and the eosinophil
density. Biopsy was performed at the time of diagnosis and
was not repeated at the time of IS induction for ethical
reasons.
Statistical analysis
Eosinophils and CD4/CD8 were analyzed as continuous
parameters and also as dichotomous according to clinical
relevance cutoffs: 3% for eosinophils and 2.5 for CD4/CD8.
Comparisons between the study and control groups with
regard to demographic parameters (sex, age), PFT results
and differential cell count results were done using the
ManneWhitney non-parametric, Chi-square and Fisher’s
exact tests. Spearman correlation coefficients were calcu-
lated in order to examine the relationships between all
continuous parameters. The association between inflam-
matory and functional parameters and the type of treat-
ment and extent of disease in the UC group was examined
using the ManneWhitney non-parametric test. Significance
was set at a p value of less than 0.05 and the SPSS, for
windows, software, version 14.0 (Chicago, IL) was used for
the analysis.
Results
All study participants underwent sputum induction and
PFTs. The IS samples of 2 UC patients contained >75%
epithelial squamous cells and those samples were dis-
carded. The IS samples of the remaining 17 UC patients
displayed a significantly higher percentage of eosinophils
than the control group (5.4 9.6% vs 0.49 1.0%,
pZ 0.0001, pZ 0.02 adjusted to age) and a lower FEV1/
FVC ratio (77.6 6.03 vs 85.6 7.7%, pZ 0.0001,
pZ 0.046 adjusted to age). No significant differences were
found in the other examined parameters (Table 2). Ten of
the UC patients had an FEV1/FVC ratio< 80% but there was
no reversion of the obstructive pattern after beta 2 agonist
treatment.
Inflammatory and functional parameters in the UC
patients were correlated with the treatment and the extent
of disease. Both the non-treated patients and those
receiving 5-ASA (nZ 11) had significantly higher percent-
ages of eosinophils and lymphocytes than those treated
with steroids or azathioprine (nZ 8, 6.7 10.7% vs
1.1 1.9, pZ 0.046 and 19.2 3.4 vs 11.6 4.8,
pZ 0.044, respectively). An inverse pattern was observed
in biopsies: eosinophils were lower in the patients treated
with 5-ASA and in the patients not receiving treatment than
Table 2 Demographic characteristics and results of the pulmonary function tests and differential cell counts of the study and
control groups.
Ulcerative colitis
(NZ 19)
Controls
(NZ 27)
p Valuea p Valueb
Age (years) 46.4 11.3 35.4 9.7 0.001
Neutrophils (%)c 41.4 23.2 46.9 21.5 0.44
Eosinophils (%)c 5.4 9.6 0.49 1.0 0.0001 0.02
Lymphocytes (%)c 12.9 5.4 14.2 7.14 0.7
Macrophages (%)c 40.2 22.2 38.4 20.2 0.86
CD4/CD8 2.8 1.76 2.6 1.25 0.94
FEV1 (%)
d 91.5 14.7 96.6 12.2 0.24
FVC (%)d 97.5 13.8 96.6 12.2 0.78
FEV1/FVC 77.6 6.03 85.6 7.7 0.0001 0.046
DLCO (%)d 81.9 17.7 84.7 9.38 0.96
FEV1 e flow expiratory volume in 1 s; FVC e forced vital capacity; DLCO e diffusion lung carbon monoxide.
a ManneWhitney non-parametric test.
b Adjusted to age.
c Percent of 300 cells counted as described in Methods.
d Percent prediction.
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(59.7 37 vs 142.6 10, pZ 0.044). UC patients with
limited proctitis showed higher percentages of eosinophils
than those with extensive proctitis and pancolitis
(10.4 13.8% vs 1.9 2.4%, pZ 0.05). The same inverse
pattern was observed in tissue biopsies of proctitis patients
with fewer eosinophils than in those of patients with pan-
colitis (61.2 42.1 in proctitis vs 96.2 85.7 in pancolitis),
but the difference did not reach a level of significance
(pZ 0.44). As for PFT results, the patients with extensive
UC who were treated with steroids or azathioprine had
lower FEV1/FVC ratios and forced expiratory flow at 50%
vital capacity (FEF50) than non-treated patients and proc-
titis patients receiving 5-ASA (79.7 4.8 vs 71.8 5.6,
pZ 0.019 and 79.1 23.9 vs 51.5 14.4, pZ 0.015,
respectively), but lower FEV1/FVC ratios and lower FEF50
levels (80.3 3.2 vs 75.6 6.9, pZ 0.19 and 86.7 6.8 vs
62.1 28.4, pZ 0.015, respectively, Table 3). Fig. 1Table 3 Inflammatory and functional parameters according to
(19 patients).
EOS-IS (IS) (%)a
Treated with 5-aminosalicylic acid
or not treated (NZ 14)
6.7 10.7
Treated with steroids or azathioprined (NZ 5) 1.1 1.9
pZ 0.046
Proctitis (NZ 7) 10.4 13.8
Extensive UC (NZ 12) 1.9 2.4
pZ 0.05
All p values are obtained by the ManneWhitney non-parametric test.
EOS-IS (IS) e eosinophils in induced sputum; EOS-biopsy e eosinophils
expiratory volume in 1 s; FVC e forced vital capacity; FEF e flow exp
a Counts undertaken from 5 randomly chosen area (Methods).
b Percent of 300 cells counted (cells/mm2).
c Percent prediction.
d Some also received 5-aminosalicylic acid.displays a representative patient with abundant eosinophils
in biopsy but not in his IS, and Fig. 2 shows a representative
patient with scarce eosinophils in biopsy and abundant in
sputum.
The patients and controls were divided into 4 groups
according to the cutoffs of eosinophils and T-cell subsets
which are known to have clinical relevance, i.e., 3%
eosinophils, >3% eosinophils, 2.5 CD4/CD8 and >2.5 CD4/
CD8 (Fig. 3). Similar number of patients were found to have
higher CD4/CD8 ratios compared to the control group (9/17
vs 12/24, respectively, pZ 1.0), while more patients with
UC had percentage of eosinophils> 3% than controls (7/17
vs 1/24, respectively, pZ 0.005, Fig. 1). Moreover, the UC
patients with eosinophils> 3% in the sputum differential
counts were the ones with proctitis but not the ones with
extensive disease (pZ 0.05). These high levels of eosino-
phils were not correlated to any decreases in FEV1%
(94.3 13.8%): only 3 patients reported suffering fromthe treatment and extent of ulcerative colitis disease
EOS-biopsy (cells/mm2)a LY (%)b FEV1/FVC FEF50%
c
59.7 37 19.2 3.4 79.7 4.8 79.1 23.9
142.6 110 11.6 4.8 71.8 5.6 51.5 14.4
pZ 0.044 pZ 0.044 pZ 0.019 pZ 0.015
61.2 42.1 13.2 5.2 80.3 3.2 86.7 6.8
96.2 85.7 12.8 5.9 75.6 6.9 62.1 28.4
pZ 0.44 pZ 0.4 pZ 0.19 pZ 0.015
in biopsy; LY e lymphocytes; UC e ulcerative colitis; FEV1 e flow
iratory flow 50%.
Figure 1 (A) Sputum sample with a low content of eosino-
phils. (B) Biopsy of the same patient’s intestine showing a high
content of eosinophils.
Figure 2 (A) Sputum sample with a high content of eosino-
phils. (B) Biopsy of the same patient’s intestine showing a low
content of eosinophils.
0
5
10
15
20
<=3%EOS>3%EOS<=2.5CD4/CD8>2.5CD4/CD8
Controls 
Patients
*P=0.005
*P=0.005No patients
Figure 3 Comparison between eosinophils and T-cell
lymphocytes in the patients with ulcerative colitis compared to
the controls. CD4 e cluster of differentiation 4; CD8 e cluster
of differentiation 8; EOS e eosinophils.
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(75.9 9.1%) (Table 4).
The sensitivity, specificity and positive likelihood ratio
were the best when a cutoff of 3% of eosinophils in sputum
was used to differentiate high/low density of eosinophils in
tissue (67%, 73% and 2.44, respectively) (at a cutoff of
70 cells/mm2; Table 5).
There was no correlation between UCDAI and any of the
functional and inflammatory parameters.
Discussion
Having had demonstrated a link between IS results and
Crohn’s disease, we designed the current study to see
whether the same connection exists between IS and
another IBD, UC. We were not at all surprised to confirm
that such a relationship does indeed exist. What was
entirely unexpected was that bronchial eosinophilic infil-
tration in the IS of patients with UC was more pronounced
in mildly treated patients with less extensive disease.
Moreover, there was an inverse eosinophil accumulation in
Table 4 Correlation between eosinophil levels and func-
tional parameters according to the extent of ulcerative
colitis disease and lung involvement.
3%EOS* >3% EOSa p Valuec FEV1 (%)b p Valuec
Lung disease
Yes 0 3 0.051 75.9 9.1 0.047
No 10 4 94.3 13.8
Extent of UC
Proctitis 0 7 0.001 97.9 12.1 0.07
Extensive 10 0 86.9 15.2
*EOS e eosinophils; UC e ulcerative colitis; FEV1 e flow
expiratory volume in 1 s.
a Percent of 300 cells counted as described in Methods.
b ManneWhitney non-parametric test.
c Percent prediction.
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implement IS technology to confirm the findings of higher
eosinophil levels in rectal biopsies.
Eosinophils are involved in several chronic inflammatory
diseases that affect organ systems normally exposed to
antigens, such as the respiratory tract and the skin, and
increasing evidence suggests that they may be involved in
the pathogenesis of IBD.19,20 We performed IS in patients
with historical biopsy-proven UC and compared their
differential cell counts with those cells obtained from an
allegedly healthy control group. The question we sought to
answer is whether the sputum eosinophilia seen in the UC
patients in our study might reflect the GI tract infiltration of
eosinophils.
We had previously demonstrated that 65% of the CD
patients in spite of them being asymptomatic had an
accumulation of CD4þ cells in their IS specimens.10 These
findings were similar to those reported by Pabst and
Tschering21 in BAL samples (54% with an abnormal CD4/CD8
ratio), demonstrating that there is a migration of intestinal
lymphocytes through the general circulation22 to the
common mucosal immune system. Rutgers et al. showed
that eosinophil content was comparable in samples from IS
and BAL samples in asthmatics,23 and Wallaert et al.24
demonstrated a mucosal eosinophilic inflammationTable 5 Sensitivity, specificity and positive likelihood ratio o
eosinophils in tissue.
Eosinophils in sputum (%)b Eosinophils in biopsy (cells/mm
40 50
40 >40 50
3% 2 8 6
>3% 1 6 2
Sensitivity (%) 42.9 55.6
Specificity (%) 66.7 75
PPV (%) 85.7 71.4
NPV (%) 20 60
LR (þ) 1.29 2.2
PPV e positive predictive value; NPV e negative predictive value; LR
a Counts undertaken from 5 randomly chosen areas (Methods).
b Percent of 300 cells counted (cells/mm2).associated with a Th2 cytokine expression in the gut of
asthmatic patients, suggesting that while asthma is clini-
cally expressed in the airways, the immune abnormalities
are present throughout the mucosae.
The IS samples from our UC patients contained higher
levels of eosinophils than the samples of the control group.
These findings are supported by those of previous studies
that showed that although these cells are normally present
in the intestinal mucosa and participate in host defense,25
their numbers are highly increased in patients with UC.26
Moreover, increased levels of eosinophil granule proteins
have been detected in intestinal perfusion fluid27 and in
feces28 from patients with UC.
The functional parameters which were tested by PFT
demonstrated an obstructive pattern with a significantly
decreased FEV1/FVC ratio compared to the control group.
Our findings were similar to those recently reported by
others, by showing mostly obstructive lung diseases,5
although no restrictive pattern was apparent among our
patients. The presence of eosinophils was not correlated
with any decrease in FEV1 or with the percentage of change
in FEV1 and FEV1/FVC after bronchodilators, indicating that
the eosinophil infiltration is not correlated to an asthmatic
pattern with hyperreactivity of airways29 but rather to an
eosinophilic bronchitis pattern in which these two pathways
are unrelated.30 Eosinophilic bronchitis is recognized as
being a common but not a consistent feature of asthma and
one that can occur when symptoms are absent and the FEV1
is normal.31
Dividing IS samples into 4 groups according to the cutoffs
of eosinophils and T-cell subsets showed that the threshold
of 3% eosinophils plays a major role in differentiating UC
patients with proctitis from the UC patients with extensive/
pancolitis and from controls in a manner similar to that in
asthma and eosinophilic bronchitis.30 This cutoff is the best
for sensitivity, specificity and positive likelihood ratio to
differentiate low/high density of eosinophils in the tissue
biopsy. In contrast, there were no differences when we
used a 2.5 CD4/CD8 cutoff of T lymphocytes as we had done
earlier in patients with CD, sarcoidosis and other granulo-
matous diseases.10,32 This emphasizes the fact that these
profiles are associated with a Th2 pattern in UC driven by
the production of IL-13 and eosinophils recruitment andf induced sputum (3%) to differentiate high/low density of
2)a
60 70
>50 60 >60 70 >70
4 6 4 8 2
5 2 5 3 4
55.6 66.7
75 72.7
71.4 57.1
60 80
2.2 2.4
(þ) e positive likelihood ratio.
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and recruitment of lymphocytes.12
The eosinophil count in the lung was in contrast to the
percentage of eosinophils present in the lamina propria
being a mirror image of the intestine. We found a higher
percentage of IS eosinophils (>3%) in untreated UC patients
as well as in proctitis patients treated with 5-ASA compared
with patients who were treated with steroids or azathio-
prine and UC patients who had extensive pancolitis. A
unique feature of eosinophils is that they largely reside in
the tissues, instead of staying in the blood circulation as
neutrophils do. There is trafficking into the gastrointestinal
tract and, under homeostatic conditions, eosinophils home
into the thymus, mammary gland, and uterus. The accu-
mulation in the respiratory mucosa is selectively activated
by eosinophil-selective cytokine IL-5 and the eotaxin
subfamily of chemokines.33 The inverse differential accu-
mulation in gastrointestinal and airways mucosa is similar
to that seen in peripheral lymphopenia, with high accu-
mulation of activated lung lymphocytes in sarcoidosis.34
It should be borne in mind that treatment with 5-ASA
itself could also be responsible for pulmonary eosino-
philia.35 Although we cannot rule out an effect of 5-ASA in
some of our UC patients, the fact that patients who were
not receiving 5-ASA also clearly displayed sputum eosino-
philia indicates that factors other than a reaction to this
drug must be involved in these patients. In contrast, the
percentage of eosinophils dropped to normal levels in the
UC patients treated with steroids or azathioprine. These
findings are not unexpected since sputum eosinophilia may
be reduced by systemic corticosteroids.36 This systemic
antiinflammatory treatment, however, apparently does not
affect the airways of the UC patients since it did not
reverse their airway obstruction.
These findings raise the intriguing question about the
role of eosinophils in UC which appears not to be clear-
cut.37,38 Clinical investigations have been performed to
assess an association between eosinophil infiltration and
disease activity. Sarin et al.39 showed rectal eosinophilic
cell counts to be significantly higher in active UC than in
quiescent UC and healthy controls, but there was no
correlation between the eosinophil cell counts and disease
severity. Jeziorska et al.40 reported an increased number of
eosinophils only in active IBD and much fewer in chronic
quiescent disease. In contrast, Korelitz and Sommers41
described low mucosal eosinophil counts in active
untreated UC and no correlation between the number of
eosinophils in the lamina propria and treatment response to
sulfasalazine. Those authors demonstrated that the pres-
ence of tissue eosinophils corresponded to the general
tendency for the condition to deteriorate and require
intense medical therapy. Lampinen et al.42 further estab-
lished that the activity of eosinophils was high in active
disease. During the inactive phase of UC, the patients had
a higher number of eosinophils while being asymptomatic
both clinically and histopathologically. These observations
have sparked even more controversy, implying that eosin-
ophils might also be involved in the resolution of inflam-
mation and repair of damaged tissue, which has also been
elicited in allergy and asthma.43
There are a number of limitations to this study. The first
is the relatively small population of UC patients in the studygroup. The second is that all of the UC patients were
a priori diagnosed: in other words, sputum induction had
not been done at the time of intestinal biopsy and tissue
immunohistochemistry which were performed for diag-
nosing infiltration of eosinophils in the mucosa by
gastroenterologists.
In conclusion, we propose that eosinophil cutoff points
in the IS samples from UC patients can be used as a nonin-
vasive approach for evaluating GI mucosa for monitoring
the extent of disease and assessing treatment.
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